Search

The book covers the various cell signaling pathways responsible for prostate cancer progression, conventional therapies used for prostate cancer treatment, new emerging therapeutics, and challenges in the treatment of cancer patients. It describes the different molecular pathways responsible for prostate cancer progression to improve readers'knowledge about the role of signaling networks, and cellular and molecular aspects of prostate cancer progression. These topics include mechanisms responsible for prostate cancer malignancy with a focus on molecular pathways. It also discusses the current challenges in prostate cancer treatment such as drug resistance and immune evasion and introduces novel therapeutics such as gene therapy and nanotherapeutics for prostate cancer. This book is completely novel and unique and covers all aspects of prostate cancer progression and challenges in therapy while presenting solutions. Written by prestigious researchers around the world, this book will be interesting to researchers and practitioners, especially those working in urological cancers.

This book provides an in-depth exploration of the biology of prostate cancer, from its cellular origins to its clinical manifestations and therapeutic options. In addition to thoroughly covering a variety of diagnostic methods, radical procedures, radiation therapy, hormone therapy, and surgical techniques for prostatectomy, the book seeks to improve the understanding of the development of prostate cancer. Delving into the latest research and scientific advancements, the book starts by shedding light on the critical role of genetic susceptibility, redox signaling, apoptosis, epigenomics, transcriptomics, and metabolic reprogramming in prostate cancer development and progression. In the following section key concepts in prostate cancer diagnostics are covered. This includes the diagnostic, prognostic, and theranostic potential of miRNAs in prostate cancer; the necessity of biopsy; and the importance of histopathological and molecular markers in assessing aggressivity. It alsoexplores recent advances in tumor markers for early detection and monitoring, as well as biological markers of therapeutic response. The book concludes by offering a wealth of knowledge on current treatment options for prostate cancer, including surgical treatments, hormone therapy for advanced cases, the use of apheresis in personalized cell-mediated treatment, pharmacogenomics and precision therapy challenges and perspectives, stereotactic radiotherapy, and treatment for castration-resistant prostate cancer. Scientists and medical professionals interested in basic and clinical research in urology and oncology will find this book to be a useful reference. It is a helpful tool for preparing medical specialization in pathology, oncology, urology, clinical biochemistry, laboratory medicine, diagnostic radiology, oncologic radiology, and related fields of cancer research. With its integrative approach to diagnostics and focus on recent scientific breakthroughs, this book empowers readers to deepen their understanding of prostate cancer and enhance their ability to advance basic and clinical research to treat this pervasive disease.

This Handbook on cancer biology comprehensively reviews the current status of the oncobiology of major cancer types, cancer detection and treatment strategies, principles and processes of cancer drug development, and nanomedicine and other emerging cancer medicine applications to cancer diagnosis and treatment. The book also provides practical and implementable nutritional guidance in cancer prevention, treatment, and quality of life for cancer survivors. It discusses pharmacogenetics strategies for predicting cancer prognosis and treatment exposure, response, and toxicity. Further, it presents bioinformatics approaches for predicting anti-cancer drugs and drug combinations based on the multi-omic data, including transcriptomics, toxicogenomics, functional genomics, and biological networks. The Handbook also examines major factors and pathways that regulate cancer stem cells development and discusses potential targeted therapy for cancer stem cells. The book explores the application of the CRISPR/Cas9-based gene-editing technique in basic cancer research, diagnosis, and treatment of cancer. This Handbook is an invaluable source for oncologists, researchers, public health specialists, epidemiologists, and policy makers.​

This book, now published in its second edition, covers a wide range of topics relating to the use of radiopharmaceuticals. The basics of nuclear chemistry, radiochemistry, and radiopharmacology are considered in detail, regulatory issues are reviewed, and potential applications in drug development, translational medicine, clinical diagnostics, and targeted therapy are discussed. Compared with the first edition, the chapters on targeted therapy with alpha- and beta-emitting radiopharmaceuticals and theranostics are completely new. Other chapters have been updated and revised as necessary. Radioisotope-based molecular imaging probes (radiopharmaceuticals) provide unprecedented insights into biochemistry and function in both normal and diseased states of living systems, with unbiased in vivo measurements of regional radiotracer activities offering very high specificity and sensitivity. No other molecular imaging technology, including functional magnetic resonance imaging, can provide such high sensitivity and specificity at a tracer level. This book, written by an experienced radiochemist and scientist, offers valuable insights into the full range of applications of this technology.

This reference book compiles together different animal models in cancer research. It provides knowledge and a better understanding of the advancement of the molecular and cellular mechanisms associated with the progression, formation, and clinical results of various types of cancer from the evidence collected from animal models utilized for cancer research. It discusses animal models for screening anti-cancer drugs and exploration of gene therapy. It presents different methods used to construct cancer animal models and the progress of each animal model in tumor research. The book also highlights the applications of genetic engineering, including CRISP/Cas9, in designing and developing animal models for cancer research. Further, it discusses strategies for modeling animals for investigating growth, metastasis, tumor-associated inflammation and microenvironment, cancer stem cells, tumor heterogeneity, and therapeutic resistance. This book is s a valuable resource for basic and translational cancer researchers, clinicians, and health care.

HOLLAND-FREI CANCER MEDICINE The latest edition of the gold-standard in cancer science and clinical oncology references In the newly revised Tenth Edition of Holland-Frei Cancer Medicine, a team of distinguished researchers and practitioners delivers a comprehensive and up-to-date discussion of cancer science and clinical oncology practice. The book contains timely and indispensable information on epidemiology, etiology, cancer biology, immunology, prevention, screening, clinical presentation, pathology, imaging, and therapy. Grounded in a fundamental understanding of cancer biology, Holland-Frei Cancer Medicine combines scientific principles with clinical practice. It contains hundreds of full-color illustrations and photographs, tables, graphs, and algorithms that complement and enhance the complex topics discussed within the book. This book is an invaluable clinical tool that provides readers with overview boxes, additional references, and other pedagogic features designed to make the content easy to access and comprehend. Readers will also find: A translational and integrated approach throughout the book that combines cancer biology with cancer management A strong emphasis on multidisciplinary, research-driven patient care that improves outcomes and allows for the optimal use of all clinically appropriate therapies Discussions of the most current personalized cancer care, including molecular diagnostics and therapeutics Perfect for medical oncologists, radiation oncologists, and internists, Holland-Frei Cancer Medicine, Tenth Edition will also earn a place in the libraries of allied health professionals involved in the treatment of cancer patients. This book is published in collaboration with the American Association for Cancer Research: https://www.aacr.org/

The book provides comprehensive review of common uro-oncology cases mainly focusing on its management aspect. It includes diagnosis and clinical staging, surgical management, pathological staging, adjuvant treatment and follow up. It provides current evidence-based approaches for the management of common urological malignancies. All the chapters are written uniformly in a simple yet informative manner by experts in their respective fields. It contains well-prepared illustrations, relevant clinical images and flowcharts. The book is helpful for practicing urologists, uro-oncologists, oncologists as well as urology trainees, uro-oncology fellows in providing a holistic approach to cancer patients. It helps them to develop critical thinking and encourage discussion toward improving the overall care of the patients.

Current Cancer Biomarkers is a comprehensive review on the status of biological markers for various types of cancer. It aims to update readers on current developments on the subject. The contents are divided into 5 sections covering a wide range of biomarkers and their diagnostic applications. The range of tumour biomarkers referenced here gives insights into molecular mechanisms behind cancer, including initiation, development, progression, prognosis, response to the therapeutic modalities, recurrence, and point-of-care application to detect cancer. Key features- Introduction of the basic features of cancer markers- Comprehensive and updated coverage of potential and effective biomarkers including genomic, epigenomic, transcriptomic, proteomic, cellular and morphologic factors- Information on biomarkers in many types of cancers including breast cancer, colorectal cancer, skin cancer, leukemia, liver cancer and prostate cancer- Applications of biomarkers in cancer diagnosis- Structured contents with easy-to-understand sections and headings- References for advanced readers The updated information about different aspects of cancer markers in the experimental and clinical setting will enrich the reader's understanding of the disease. The information serves as a resource to help in better management of cancer patients and understanding cancer biology when planning medical research projects. The book is intended as a reference for a diverse audience: biomedical science students, medical students, academics, researchers, clinicians and multidisciplinary teams involved in cancer management and research.

This book addresses Epigenetics in Cancer and covers the most recent advances in RNA/histone/DNA epigenetics in Oncology. RNA/histone/DNA epigenetics have been shown to play pivotal roles in cancer initiation, progression, maintenance and drug response/resistance, tumor microenvironment, cancer stem cell self-renewal, cancer metabolism, and tumor immune evasion. In particular, research in RNA cancer epigenetics has made impressive progress in the last few years.Individual chapters in Part I (focusing on RNA epigenetics) are devoted to RNA modifications in Cancer Metabolism and Microenvironment, Cancer Stem Cell Biology, Immune Surveillance, Solid Tumors and Tumor Immunity, and Hematopoietic Malignancies, as well as to RNA editing in Cancer. Chapters in Part II and III of the book focus on histone epigenetics and DNA epigenetics, respectively.By familiarizing readers with the latest developments in this complex and challenging field, the book offers a valuable resourcefor scientists, graduate students and clinicians alike.

This book aims to address the infusion sequence of the main protocols used in the treatment of varied solid cancers. Since an inadequate infusion sequence can compromise the patient's treatment, this work will provide support to professionals working in the field of oncology in assessing each chemotherapy infusion sequence. The introductory chapters present the definition, indication, and the risks and benefits of polypharmacy in cancer therapy, and discuss the importance of drug combination in cancer treatment. Chapter 2 focuses on the challenges and also the toxicity of combination therapy in cancer, while chapter 3 highlights the parameters that must be evaluated before defining the infusion sequence, such as pharmacodynamic and pharmacokinetic profiles, drugs'stability when diluted or reconstituted, toxicological profile of each drug, among others.The remaining chapters are divided by type of cancer. The content is focused on solid tumors, dividing the chapters according to breast, gastrointestinal, genitourinary, gynecological, head and neck, lung, and neurological cancers. In each chapter the epidemiological profiles, pathophysiology, therapeutic modalities, and the main chemotherapy protocols are addressed, as well as efficacy studies and data on the infusion sequence of each mentioned protocol.This work will be a valuable resource to physicians, nurses, and pharmacists, and may help to improve health service practices.

The standard-setting text in oncology for 40 years, DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology, 12th Edition, provides authoritative guidance and strategies for managing every type of cancer by stage and presentation. Drs. Vincent T. DeVita, Jr., Theodore S. Lawrence, and Steven A. Rosenberg oversee an outstanding team of expert contributing authors who keep you up to date and fully informed in this fast-changing field. This award-winning reference is also continually updated on Health Library and VitalSource platforms for the life of the edition.

This reference book, which is the second volume of Targeting Oxidative Stress in Cancer, explores oxidative stress as the potential therapeutic target for cancer therapy. The initial chapters discuss the molecular mechanisms of oxidative stress and its effects on different signaling pathways. Subsequently, the sections examine the impact of redox signaling on tumor cell proliferation and consider the therapeutic potential of dietary phytochemicals and nutraceuticals in reactive oxygen species (ROS)-induced cancer. In turn, it examines the evidence supporting the use of Vitamin C in cancer management, before presenting various synthetic and natural compounds that have therapeutic implications for oxidative stress-induced cancer. It also explores the correlation between non-coding RNA and oxidative stress. Furthermore, the book summarizes the role of stem cells in ROS-induced cancer therapy and reviews the therapeutic applications of nanoparticles to alter redox haemostasis in cancer cells. Lastly, it explores heat-shock proteins, ubiquitin ligases, and probiotics as potential therapeutic agents in ROS-mediated cancer. This book is a useful resource for basic and translational scientists as well as clinicians interested in the field of oxidative stress and cancer therapy. ​

Comprehensive, authoritative, and up to date, Oncologic Imaging: A Multidisciplinary Approach, 2nd Edition, covers every aspect of radiographic imaging for the diagnosis, treatment, and management of the cancer patient. Dr. Paul M. Silverman and an expert author team from MD Anderson Cancer Center provide all the current, practical information available, while incorporating their unique experience based upon extensive, daily clinical care of patients with cancer. In one convenient volume, this definitive, one-of-a-kind text discusses new diagnostic imaging and surgical approaches as well as therapeutic cutting-edge treatments from radiation and medical oncology, focusing on best practices and the newest standards for personalized medicine. - Brings together a unique multidisciplinary team of authors including clinical radiologists, medical oncologists, radiation oncologists, and surgical oncologists who reflect team-based practice. - Features an all-new chapter on head and neck imaging, authored by world experts in this complex area. - Contains extensive updates throughout, including transformational state-of-the-art imaging modalities such as PET/CT, and the full range of traditional modalities, including multidetector CT (MDCT), ultrasound, and MR in conjunction with the latest advances in genetics, molecular oncology, and targeted therapies. - Distills practical, up-to-date information into a concise and consistent format with key point summaries, algorithms, clear drawings, and full-color staging diagrams. - Includes emerging options for care based on practice recommendations and evidence in the literature. - Provides updated tumor staging information based on the AJCC Classification of Malignant Tumors, 8th edition. - Highlights the text with 1,000 high-quality radiographic images: CT, MR, hybrid imaging (PET/CT, PET/MR), mammography, and ultrasound, as well as clear line anatomic drawings, graphs, and algorithms.

Recent scientific advances have revolutionized cancer research and practice, creating a body of molecular biology information that is important to research scientists and clinical oncologists alike. Cancer: Principles and Practice of Oncology: Primer of the Molecular Biology of Cancer, 3rd Edition, keeps you up to date with all that's new in this rapidly changing field. Derived from DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology – widely regarded as the definitive clinical reference in oncology – the third edition of this popular Primer provides a single-volume, highly focused reference on every important frontier in the molecular biology of cancer.

Treatment of Cancer is a multi-author work and comprehensive guide on modern cancer treatment that aims to give clinician and student alike the framework for an integrated approach to patient care, including radiotherapy, chemotherapy, and surgery. Much information is presented in tables and charts for easy assimilation, and clear algorithms for patient pathways are included to make decisions straightforward while allowing for sound clinical judgement.

Evidence-based, superbly illustrated, and easy to read, Berek & Hacker's Gynecologic Oncology, Seventh Edition, remains your reference of choice for authoritative information on every aspect of gynecologic malignancies. Templated chapters provide quick access to guidance on everything from general principles through diagnosis and medical and surgical management. This fully revised edition offers the practical, state-of-the-art coverage you need when caring for women with preinvasive disease; ovarian, breast, uterine, cervical, vulvar, and vaginal cancers; and gestational trophoblastic disease.

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers. The seventh volume of the book features reviews on these topics:

This textbook combines essential information on clinical cancer medicine with a guide to the latest advances in molecular oncology and tumor biology. Providing a systematic overview of all types of solid tumors, including epidemiology and cancer prevention, genetic aspects of hereditary cancers, differential diagnosis, typical signs and symptoms, diagnostic strategies and staging, and treatment modalities, it also discusses new and innovative cancer treatments, particularly targeted therapy and immunotherapy. Expert commentaries at the end of each chapter highlight key points, offer insights, suggest further reading and discuss clinical application using case descriptions. This textbook is an invaluable, practice-oriented tool for medical students just beginning their clinical oncology studies, as well as for medical oncology residents and young professionals.

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers.The sixth volume of the book features reviews on these topics:· Immunomodulating Agents in The Treatment of Acute Myeloid Leukemia· Potential Natural Products for Prostate Cancer Management· Inhibition of Key Protein-Protein Interactions by Small Molecules for Cancer Drug Design· Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) For Advanced Hepatocellular Carcinoma· Targeting Cancer Stem Cells: Implications in Health and Disease

Leading scientists argue for a new paradigm for cancer research, proposing a complex systems view of cancer supported by empirical evidence.Current consensus in cancer research explains cancer as a disease caused by specific mutations in certain genes. Thanks to dramatic advances in genome sequencing, never before have we known so much about the individual cancer cell—and yet it is still unclear how to use this knowledge for treatment success. In this volume, leading researchers argue for a new theory framework for understanding and treating cancer. The contributors propose a complex systems view of cancer, presenting conceptual building blocks for a new research paradigm supported by empirical evidence. The contributors first discuss the new research framework in terms of theoretical foundations and then take up the relevance of a systems approach, reviewing such topics as nonlinearity, recurrence after treatment, the cellular attractor concept, network theory, and noncoding DNA—the “dark matter” of our genome. They address the temporality of cancer progression, drawing on evolutionary theory and clinical experience. Finally, they cover the dominant role of the tissue microenvironment in cancer, analyzing topics including altered metabolic pathways, the disease-defining influence on metastasis, and the interconnectedness of different environmental niches across levels of organization.

This book reviews the latest developments in the design, synthesis, and molecular mechanism of action of Histone Deacetylase (HDAC) inhibitors in the context of potential cancer therapy. HDAC inhibitors are emerging as promising anticancer drug molecules that promote growth arrest, differentiation and apoptosis of cancer cells with tumor selective toxicity. The book begins with an overview of various epigenetic modifying enzymes that are involved in cancer transition and progression; before exploring the potential of HDACs in cancer treatment. It provides a classification of HDAC inhibitors based on their structural attributes, and addresses HDAC-induced cytotoxicity.. Lastly, it discusses and assesses the rationale behind therapies that combine HDAC inhibitors with other anticancer agents to treat solid tumors. Given its scope, it offers a valuable resource for all researchers, clinicians, and students working in formulation, drug discovery, oncology, and personalized medicine.

Publisher's Note: Products purchased from 3rd Party sellers are not guaranteed by the Publisher for quality, authenticity, or access to any online entitlements included with the product. Now updated online for the life of the edition, DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 11th Edition keeps you up to date in this fast-changing field. Every quarter, your eBook will be updated with late-breaking developments in oncology, including new drugs, clinical trials, and more.

This updated volume provides a concise evidence based overview of the field of contemporary urological practice. There are new chapters covering urologic imaging, the upper tract urothelial carcinoma, the treatment of adult male hormonal disorders, the management of urethral stricture disease, and the treatment of renal cancer. The anatomy and physiology of the urinary tract, the basis and principles for development of urologic diseases, and the evaluation and management of urologic diseases are also covered. Urologic Principles and Practice is relevant for practicing urologists, urology trainees, allied health professionals, medical students, and researchers.

This book presents a unique concept of merging nanotechnology and novel urinary biomarkers for accurate early prostate cancer detection, discussing an entire progressive pipeline of innovative new strategies in biosensor development, from a simple colorimetric system to a complex system for simultaneous multiple biomarker sensing. For newcomers to the field of nucleic acid biosensing, it also describes various isothermal amplification and amplification-free strategies, which are currently the main research areas. Lastly, the book introduces and demonstrates the notion of clinical nanobiosensor validation toward clinical translation: the ultimate aim of researchers in the biosensor field. This book is a valuable reference resource learners seeking inspiration for cancer biosensor development.

This comprehensive and timely textbook covers all aspects of the evidence-based management of genitourinary cancers and explains the fundamental principles underlying the available diagnostic and treatment approaches, including chemotherapy, radiotherapy, immunotherapy, and surgery. For each type of cancer – prostate, bladder, renal, testicular, and penile, plus rare urologic malignancies – clinical presentation, diagnosis, and treatment strategies are described in detail and information is provided on etiology, epidemiology, risk factors, and pathology, including TNM classification. Careful attention is also devoted to the complications that may be encountered when treating urologic malignancies and to the management of these complications. The text is complemented by the inclusion of numerous high-definition photographs and illustrations. Urologic Oncology will be a valuable reference and source of guidance for all oncologists, urologists and practitioners in related disciplines who treat patients with urologic cancers.

​The recent advances in genomics are continuing to reshape our approach to diagnostics, prognostics and therapeutics in oncologic and other disorders. A paradigm shift in pharmacogenomics and in the diagnosis of genetic inherited diseases and infectious diseases is unfolding as the result of implementation of next generation genomic technologies. With rapidly growing knowledge and applications driving this revolution, along with significant technologic and cost changes, genomic approaches are becoming the primary methods in many laboratories and for many diseases. As a result, a plethora of clinical genomic applications have been implemented in diagnostic pathology laboratories, and the applications and demands continue to evolve rapidly. This has created a tremendous need for a comprehensive resource on genomic applications in clinical and anatomic pathology. We believe that our current textbook provides such a resource to practicing molecular pathologists,hematopathologists and other subspecialized pathologists, general pathologists, pathology and other trainees, oncologists, geneticists and a growing spectrum of other clinicians. With periodic updates and a sufficiently rapid time from submission to publication, this textbook will be the resource of choice for many professionals and teaching programs. Its focus on genomics parallels the evolution of these technologies as primary methods in the clinical lab. The rapid evolution of genomics and its applications in medicine necessitates the (frequent) updating of this publication.This text will provide a state-of-the art review of the scientific principles underlying next generation genomic technologies and the required bioinformatics approaches to analyses of the daunting amount of data generated by current and emerging genomic technologies. Implementation roadmaps for various clinical assays such as single gene, gene panels, whole exome and whole genome assays will bediscussed together with issues related to reporting and the pathologist's role in interpretation and clinical integration of genomic tests results. Genomic applications for site-specific solid tumors and hematologic neoplasms will be detailed. Genomic applications in pharmacogenomics, inherited genetic diseases and infectious diseases will also be discussed. The latest iteration of practice recommendations or guidelines in genomic testing put forth by stakeholder professional organizations such as the College of American Pathology and the Association for Molecular Pathology, will be discussed as well as regulatory issues and laboratory accreditation related to genomic testing. All chapters will be written by experts in their fields and will include the most up to date scientific and clinical information.

This fully updated second edition provides a comprehensive, state of the art review of renal cancer, and will serve as a guide for urology residents, clinicians, surgeons, and researchers with an interest in renal cell carcinoma. The title reviews the latest information regarding epidemiology, clinical staging, molecular biology and genetics, hereditary syndromes, pathology, imaging, molecular imaging, interventional radiology, surgical advances, and the unified approach to surgery and systemic therapy of renal cell carcinoma. It also addresses the management of localized RCC, locally advanced disease, and advanced disease.A valuable resource for physicians and researchers dealing with renal cancer, Renal Cancer: Contemporary Management, Second Edition provides a comprehensive summary of the field that will guide patient management and stimulate further clinical and basic science research efforts.

This book, conceived as an atlas with emphasis in diagnostic images, presents some tumors displaying expected clinical, histological or biological behavior but in most of them that differs from that usual morphology or clinical behaviour. About 132 tumors of the testicles and paratesticular structures have been selected, representing all the testicular and paratesticular tumor groups, including germinal, gonadal stromal, non-gonadal stromal, rete testis tumors, ovarian-type epithelial tumors, and epididymis, spermatic cord and testicular covers as well as metastatic tumors.The format with large number of images allows pathologists to identify the entities included at a glance. Each section corresponds to one case including a brief clinical history, a concise histological description with immunohistochemical techniques necessary to confirm the diagnosis. In addition, each section provides several sample images, with histological details of the appropriate morphological or characteristic immunoexpression of diagnostic markers and in the majority of cases gross or radiologic figures. Finally, each section ends with a comment on the problems of differential diagnosis that could arise. The book is intended for pathologists, urologists and oncologists.

This book offers an updated review of malignant mesothelioma, including the latest advances in our understanding of its genetic control and molecular biology, as well as pre-clinical and clinical research. It also presents state-of-the-art diagnostic approaches and therapeutic options, and an open discussion on the future prospects for patient management. Malignant mesothelioma is an enormous global health problem related to asbestos exposure. Despite the best efforts of scientists and oncologists, the prognosis for those affected remains poor. Due to anatomical characteristics and non-specific symptoms, the diagnosis of mesothelioma at an early stage is often difficult, while surgery and radiotherapy are only of limited use, even if some multimodality approaches seem promising. In turn, medical treatments are sometimes successful in tumor control, but have little impact on overall survival. However, advances in our understanding of the disease's biology, together withthe availability of new drugs and combinations, make mesothelioma an essential and highly topical field for pre-clinical and clinical studies. This book is subdivided into four parts: epidemiology and preclinical data, diagnosis, therapy, and extrathoracic mesothelioma. It highlights the progress made in a variety of areas – e.g. in vitro and in vivo experimental models, genetics, environment, biomarkers, targeting agents, immunotherapy, metabolic imaging and ongoing clinical trials – and describes the standard clinical management of mesothelioma patients, including those with extra-thoracic localizations. Given its scope, the book offers an invaluable tool for researchers, oncologists and clinicians alike.

Resveratrol is a structurally simple, grape-derived polyphenol with seemingly boundless biological activities. The Editors have assembled a group of renowned scientists who have illustrious careers and lifelong passions for studies of this compound. Each chapter covers topics using published and, at times, unpublished data to provide scholarly and comprehensive reviews and perspectives. Several areas with basic clinical and public health interests are highlighted. The book is intended to serve as a text and reference covering recent research findings and clinical applications in the field.The content is presented in several parts: mechanistic leads provided by laboratory studies of resveratrol; cellular and molecular targets of resveratrol; modulation of disease states by resveratrol; virtual leads and drug discovery.

This book addresses the most pressing current questions in the management of urologic malignancies. The rapid advances in imaging and molecular markers are placed into a clinical context, with explanation of their effects on prognosis and treatment planning. Similarly, progress in immunotherapy is carefully examined, focusing in particular on the role of immune checkpoint inhibitors in both early- and late-stage urologic malignancies. Looking beyond the improvements in minimally invasive techniques for urologic cancers, the impacts of care coordination pathways and enhanced recovery after surgery protocols are reviewed. Readers will also find enlightening discussion of the decision algorithm for the treatment of early-stage, high-grade bladder cancer, taking into account evidence on the most advanced treatment options and the circumstances in which surgery may need to be expedited. The penultimate chapter discusses the Cancer Genome Atlas project for bladder cancer, and the book closes by considering contemporary medical and surgical management of testicular cancer.

This textbook summarizes the state of the art in the management of locally advanced and metastatic prostate cancer with the aim of providing the knowledge required for optimal treatment decision making in individual cases. Readers will find comprehensive coverage of the latest developments in surgery, radiotherapy, androgen deprivation therapy (ADT), chemotherapy, and immunotherapy. The role of the hormonal therapies abiraterone and enzalutamide and docetaxel-based chemotherapy in castration-resistant prostate cancer and hormone-sensitive metastatic disease is carefully evaluated. Among the other therapies discussed are LHRH agonists and antagonists, cabazitaxel, radium-223, and various novel agents still under clinical trials. The section on surgical approaches addresses, among other topics, the use of robot-assisted radical prostatectomy, pelvic lymphadenectomy, and the benefits of adjuvant and neoadjuvant therapy. The current role of external beam radiotherapy, alone or in combination with ADT and brachytherapy, for locally advanced disease is reviewed. Management of Advanced Prostate Cancer will be a valuable resource for practitioners at all levels of expertise.

This comprehensive reference expounds the current state of hormone therapy and castration resistance of prostate cancer (PCa). Previously, the incidence of PCa in Asian countries was relatively low, but it has been increasing dramatically in recent years. Although most of the new cases are diagnosed in early stages, a significant proportion of patients receive hormone therapy for metastatic disease or for relapse after local treatment. Thus the situation has gradually changed toward earlier and longer use of hormone therapy. The malignancy finally forms castration-resistant prostate cancer (CRPC) despite the lack of testicular androgen. With advances in understanding of the molecular basis of hormone dependence and CRPC, many new androgen receptor-targeted agents have emerged. During the last decade, much evidence on hormone therapy has been accumulated in Japan. Interestingly, some of these findings are different from those reported from Western countries, suggesting ethnicvariation in the outcome of hormone therapy. In the chapters of this book, expert authors provide exhaustive interpretations of the evidence recently reported from Japan and provide important Asian perspectives on hormone therapy for PCa. This work benefits not only Asian urologists but also their Western counterparts and all physicians and medical personnel who are involved in the treatment of PCa.

This volume focuses on our current understanding of the molecular underpinnings of prostate cancer and their potential application for precision medicine approaches. The emergence and applications of new technologies has allowed for a rapid expansion of our understanding of the molecular basis of prostate cancer and has revealed a remarkable genetic heterogeneity that may underlie the clinically variable behavior of the disease. The book consists of five sections which provide insight about the following: (1) General principles; (2) Molecular signatures of primary prostate cancer; (3) Molecular signatures of advanced prostate cancer; (4) Key molecular pathways in prostate cancer development and progression; (5) and Precision medicine approach: Diagnosis, treatment, prognosis. Precision Molecular Pathology of Prostate Cancer is an important resource for the practicing oncologist, urologist, and pathologist, and will also be useful for researchers in the prostate cancer community.

Developed by the American Cancer Society this new textbook designed for a wide range of learners and practitioners is a comprehensive reference covering the diagnosis of cancer, and a range of related issues that are key to a multidisciplinary approach to cancer and critical to cancer control and may be used in conjunction with the book, The American Cancer Society's Oncology in Practice: Clinical Management. Edited by leading clinicians in the field and a stellar contributor list from the US and Europe, this book is written in an easy to understand style by multidisciplinary teams of medical oncologists, radiation oncologists and other specialists, reflecting day-to-day decision-making and clinical practice. Input from pathologists, surgeons, radiologists, and other specialists is included wherever relevant and comprehensive treatment guidelines are provided by expert contributors where there is no standard recognized treatment. This book is an ideal resource for anyone seeking a deeper understanding of cancer prevention, screening, and follow-up, which are central to the ACS's worldwide mission on cancer control.

This fully updated and revised new edition provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in prostate cancer. The book reviews new data about molecular characteristics of the disease, profiles the new grading system for prostate cancer introduced in 2015, and provides new perspectives about imaging of prostate cancer, as well as the role of targeted biopsies. The text summarizes the role of biomarkers and MRI in patient selection and management and details the world wide results of active surveillance. Specific chapters address communication and ethical issues, QOL outcomes, economic aspects, and psycho-social aspects of surveillance. The role of focal therapy for low risk disease is summarized, and the data supporting preventive interventions during surveillance reviewed. This text will serve as a very useful resource for physicians and researchers dealing with,and interested in this common malignancy, as it provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts.

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.

Praise for the previous edition:“This book is a milestone and must-have for anyone involved in the care of those with cancer.'--American Journal of Physical Medicine and Rehabilitation“This reference provides a comprehensive, pragmatic approach for physical medicine physicians; speech, occupational, and physical therapists; and nurses with cancer survivor responsibilities…[A]ny cancer program with significant rehabilitation services will find this a useful addition to its library.”--JAMA (Journal of the American Medical Association)This completely revised second edition of the gold-standard reference on cancer rehabilitation provides a state-of-the-art overview of the principles of cancer care and best practices for restoring function and quality of life to cancer survivors. Authored by some of the world's leading cancer rehabilitation experts and oncology specialists, the book opens with primer-level discussions of the various cancer types and their assessment and management, including potential complications, as a foundation for providing safe and effective rehabilitation. Subsequent sections thoroughly explore the identification, evaluation, and treatment of specific impairments and disabilities that result from cancer and the treatment of cancer. Designed to serve the needs of the entire medical team, this singular resource is intended for any clinician working with cancer survivors to improve function and quality of life. With several new chapters on topics such as inpatient cancer rehabilitation, pediatric oncology, research issues, and barriers to accessing cancer rehabilitation and building a cancer rehabilitation program, the book keeps pace with recent advances in the growing field of cancer rehabilitation. This new edition features updates throughout and expansions to major topics, including imaging in cancer and key disorders such as aromatase inhibitor-induced arthralgias. Presenting the most current medical, clinical, and rehabilitation intelligence, this is a mandatory reference for anyone in the field.Key Features:New edition of the only contemporary comprehensive text covering the field of cancer rehabilitationRevised and updated to reflect current knowledge, practice, and emerging topicsCovers essential aspects of oncology and medical complications of cancer to inform rehabilitation decisions and strategiesProvides state-of-the-art reviews on all major topics in cancer rehabilitation, including pain assessment and management, neuromuscular and musculoskeletal dysfunction, neurologic, and general rehabilitation issues13 new chapters and expanded coverage of signature areasKey points are provided for each chapter to reinforce learning

Prepared by world leaders on this topic, Biomarkers in Cancer Screening and Early Detection offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers, from their discovery and development to their validation, clinical utility, and use in developing personalized cancer treatment. Offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers Provides immediately actionable information – and hopefully also inspiration – to move discovery and clinical application forward Offers vital knowledge to help develop personalized cancer treatment for individual patients with specific cancers

Two sigma receptor subtypes have been proposed, sigma1 and 2. Much of our understanding of this system is based on biochemical and pharmacological characterization of the cloned sigma1 receptor subtype (Sigma1). It has become clear that sigma receptors are not canonical receptors. Sigma1 is highly conserved among mammalian species, however, it does not share significant homology with any other mammalian protein. Although a range of structurally diverse small molecules bind Sigma1 with high affinity, and it has been associated with a broad range of signaling systems, Sigma1 itself has no known signaling or enzymatic activity. The evolution of this field over nearly four decades has more recently led to a fundamental shift in the concept of “sigma receptors” to what may more accurately and generally be called sigma proteins. Largely based on traditional pharmacologic approaches, the Sigma1 protein has been associated with a broad range of signaling systems, including G-protein coupled receptors, NMDA receptors, and ion channels. Sigma proteins have been linked to a range of physiological processes, including intracellular calcium signaling, neuroprotection, learning, memory, and cognition. Emerging genetic, clinical, and mechanism focused molecular pharmacology data demonstrate the involvement of proteins in a range of pathophysiologies and disorders including neurodegenerative disease, pain, addiction, psychomotor stimulant abuse, and cancer. However, an understanding of the physiological role of sigma proteins has remained elusive. Emerging data associate Sigma1 with chaperone-like activities or molecular scaffold functions. This book aims to provide an updated perspective on this rapidly evolving field undergoing changes in fundamental concepts of key importance to the discipline of pharmacology. It focusses on the reported roles of sigma proteins in pathophysiology and on emergent therapeutic initiatives.

Handbook of Prostate Cancer and Other Genitourinary Malignancies provides a patient-centered, practical approach to diagnosis, treatment, and clinical management of cancers found in the genitourinary system. With the recent surge of new available treatments, new AJCC Staging guidelines and changes in approaches to care, remaining current and up-to-date can be extremely challenging for practicing clinicians. This comprehensive, multidisciplinary handbook is designed with the busy oncologist, urologist, general practitioner, and trainee in mind.The handbook discusses the standards and controversies of care for managing each genitourinary malignancy and stage of disease, including expert insight and recommendations for making treatment decisions from oncologists and urologists. Clearly marked key points emphasize the most important concepts in each chapter, while numerous tables and figures summarize and highlight important information for quick reference. Handbook of Prostate Cancer and Other Genitourinary Malignancies is an indispensable guide for all oncologists, urologists, and practitioners who regularly care for prostate cancer patients and patients with kidney cancer, bladder cancer, upper urothelial tract cancer, testicular cancer, or penile cancer.Key Features:Delivers the need-to-know points of prostate cancer screening, including recommendations on how to assess severity, avoid misdiagnosis, and mitigate overtreatment of low-grade prostate cancerProvides clinical pearls and treatment recommendations for patients who don't ‘fit'the standard guidelinesCovers all FDA-approved therapies for each genitourinary malignancy and indicates therapies that are in clinical trialsPrepares physicians for challenging case scenarios and treatment decisions where controversies to clinical management persistIncludes recommendations and best practices for follow up and survivorship careSummarizes AJCC staging criteria from the 8th Edition

This text highlights seminal discoveries and also provides comprehensive and state-of the-art approach to mouse models of human patient tumors. These areas include training, basic techniques, as well as general troubleshooting. Subsequent chapters focus on the different mouse models of patient tumors including the various strains of immunodeficient mice currently available and the transplantation techniques that can be used as well as state-of-the-art imaging techniques. Practical applications of the models from drug discovery, genome analysis to personalized treatment are also covered. Written by experts in that field, each of these sections address these critical issues. A brief review of the existing literature addressing the particular topic follows in each section.Presently, there is no single source to provide information on technique and uses of mouse models of human patient tumors. Patient-Derived Mouse Models of Cancer will satisfy this need for cancer researchers, oncologists, pharmaceutical and biotechnology industry scientists as well as molecular biologists studying in vivo systems

Cancer is a multifaceted and genomically complex disease and data obtained through high throughput technologies has provided near complete resolution of the landscape of how genomic, genetic and epigenetic mutations in cancerous cells effectively influence homeostasis of signaling networks within these cells, between cancerous cells, tumor microenvironment and at the organ level. Increasingly sophisticated information has helped us in developing a better understanding of the underlying mechanisms of cancer, and it is now known that intra-tumor genetic heterogeneity, cellular plasticity, dysregulation of spatio-temporally controlled signaling cascades, and loss of apoptosis are contributory in cancer development, progression and the development of resistance against different therapeutics. It is becoming progressively more understandable that earlier detection of pre-existing or emerging resistance against different therapeutics may prove to be helpful in personalizing the use of targeted cancer therapy. Despite the fact that there is a continuously increasing list of books, being guest edited by researchers, books on the subject are often composed of invited reviews without proper sequence and continuity and designed for a particular readership. This book progressively shifts and guides the readers from basic underlying mechanisms to translational approaches to treat cancer.

This book, now in an extensively revised second edition, provides an exhaustive review of the state of the art in the management of prostate cancer, from screening to treatment, with emphasis on a multidisciplinary approach. The editors are very excited about the outstanding new or updated contributions from the different expert authors. The opening chapters address basic aspects including epidemiology, pathology, biology, genetics, and chemoprevention. The role of individual and mass screening is carefully appraised, and extensive attention is devoted to diagnosis and clinical work-up by means of recently implemented investigations such as multiparametric MRI and choline PET-CT. The use of active surveillance is examined in detail. Subsequent chapters discuss the different therapies that may be employed: open and minimally invasive, including robot-assisted, radical prostatectomy, the various forms of radiation treatment, high-intensity focused ultrasound, cryotherapy, hormonal manipulations, chemotherapy, targeted therapies, and immunotherapy. Up-to-date results from practice-changing phase III randomized clinical trials are included and special insights are provided into the interpretation of results and the patient's perspective.

This book presents up-to-date information on one of the hottest topics in prostate cancer, namely bone metastases. The most recent developments with respect to biology, pathology, diagnosis, and treatment are described, providing readers with an excellent understanding of the mechanisms of metastasis formation, the characteristics of metastases, their aggressiveness, and prognostic factors for treatment response. The coverage includes discussion of all of the best available options (laboratory, radiology, and nuclear medicine) for achieving early diagnosis and both established and novel therapeutic approaches. Detailed information is provided on hormonal manipulations, bone-targeted agents, vaccines, taxanes, and other treatments that are enriching the therapeutic armamentarium. The editors can be considered leaders in the field, with great experience in diagnostic and clinical oncology and research, and the authors are experts in diverse specialties. This ensures a multidisciplinary approach, mirroring the current situation in which treatment in patients with bone metastases is undertaken by a team of specialists and health professionals in a variety of fields.

Reflecting the increasing interest in fertility management for pediatric and adolescent patients and fulfilling an urgent need to have a comprehensive guide to the management of these individuals, this is the first book of its kind to present a comprehensive discussion of pediatric and adolescent oncofertility. It carefully examines the impact of pediatric cancer and cancer therapy on fertility and presents both current and emerging fertility preservation techniques for both males and females, such as cryopreservation. Fertility concerns beyond cancer are also discussed, including disorders of sexual differentiation, gender dysphoria and thalassemia. Practical chapters on pediatric oncofertility in the clinic round out the book, covering setting up a practice, counseling and consent, disclosure and insurance considerations. Concluding chapters document fertility preservation techniques and outcomes internationally, with contributions from Portuguese, Brazilian and Japanese authors. Timely and wide-ranging, Pediatric and Adolescent Oncofertility is an ideal resource for reproductive medicine specialists, pediatric oncologists, and primary care physicians treating pediatric and adolescent cancer patients looking to protect fertility options.

Together with Volume 1, this book provides an inclusive overview of the molecular and cellular mechanisms of carcinogenesis and offers comprehensive insights into related clinical and therapeutic aspects. This second volume complements the first by presenting and concisely explaining the carcinogenesis of various tumor entities such as non-melanoma skin cancers, bone and soft tissue tumors, pancreatic cancers, hepatocellular cancer and neuroendocrine tumors. As in volume one, each chapter illuminates the similarities and dissimilarities of changed signaling pathways in the different organ systems and depicts potential therapeutic strategies. The focus of volume two lies on the presentation of modern molecular biological techniques for diagnosis, as well as strategies for biomarker identification and validation. Furthermore, it discusses potential therapeutic targets and individualized treatment strategies, offering a valuable resource for all basic scientists and medical researchers interested in translational cancer research.

This book focuses on malignant melanoma, discussing the current state of scientific knowledge and providing insights into the underlying basic mechanisms, the molecular changes, genetics and genomics.Human Melanoma is a dangerous type of skin cancer affecting an increasing population, and a better understanding of its development will help in finding sophisticated targeted therapies.The second revised edition features the latest research findings and offers updates on the latest advances and potential novel melanoma therapies. It is a valuable resource for researchers and clinicians working in the fields of melanoma, cancer research and therapy as well as dermatology.

This evidence-based, state of the art guide to the management of urological malignancies, including bladder cancer, prostate cancer, and testicular cancer, is designed to serve as an easy-to-consult reference that will assist in daily decision making and the delivery of optimal care for individual patients within a multidisciplinary setting. Readers will find up-to-date information on patient selection and the full range of treatment modalities, including modern radiotherapy techniques, systemic chemotherapy, surgical procedures (including robotic surgery and other minimally invasive approaches), hormonal therapies, immunotherapy, and focal therapies. With regard to radiotherapy, the coverage encompasses everything from delineation of tumor volumes and organs at risk based on CT simulation through to delivery of stereotactic body radiotherapy, intensity-modulated radiation therapy, tomotherapy, volumetric modulated arc therapy, and proton therapy. The authors are leading authorities with international reputations who have been selected for their expertise in the topic that they address. The book will be of value for all practicing urooncologists as well as other oncology fellows and residents interested in urooncology.

This book offers an essential guide to RNA activation (RNAa), an emerging and fascinating new field. RNAa is a small RNA-guided and Argonaute-dependent gene regulation phenomenon in which promoter-targeted short double-stranded RNAs (dsRNAs) induce target gene expression at the transcriptional level. It occurs primarily in the nucleus and can be mediated by artificially designed short duplex RNAs that target regulatory sequences (e.g., promoters, genes'3'termini and enhancers) and naturally occurring small RNAs (e.g., miRNAs and C. elegans 22G-RNAs). With contributions from internationally respected RNA experts, this book provides comprehensive coverage of different RNAa mechanisms and a timely update on recent advances in RNAa research, with a focus on developing RNAa-based therapeutics. Special chapters are also devoted to the topics of gene activation induced by antisense oligonucleotides and the CRISPR system. As the first book to cover RNAa, it will be of interest to a wide audience, from scientists in academia and the pharmaceutical industry to clinicians who wish to further explore the biology of RNAa and related phenomena, so as to harness their full potential for use in biotechnology and drug development.